These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1505 related articles for article (PubMed ID: 32903444)

  • 21. How to overcome resistance to immune checkpoint inhibitors in colorectal cancer: From mechanisms to translation.
    Wang Q; Shen X; Chen G; Du J
    Int J Cancer; 2023 Aug; 153(4):709-722. PubMed ID: 36752642
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immune Microenvironment in Microsatellite-Instable Endometrial Cancers: Hereditary or Sporadic Origin Matters.
    Pakish JB; Zhang Q; Chen Z; Liang H; Chisholm GB; Yuan Y; Mok SC; Broaddus RR; Lu KH; Yates MS
    Clin Cancer Res; 2017 Aug; 23(15):4473-4481. PubMed ID: 28264871
    [No Abstract]   [Full Text] [Related]  

  • 23. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
    Zhang X; Wang Y; A G; Qu C; Chen J
    Front Immunol; 2021; 12():721030. PubMed ID: 34531868
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immune Checkpoint Inhibition in Colorectal Cancer: Microsatellite Instability and Beyond.
    Cohen R; Rousseau B; Vidal J; Colle R; Diaz LA; André T
    Target Oncol; 2020 Feb; 15(1):11-24. PubMed ID: 31786718
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Deficient Mismatch Repair and the Role of Immunotherapy in Metastatic Colorectal Cancer.
    Quiroga D; Lyerly HK; Morse MA
    Curr Treat Options Oncol; 2016 Aug; 17(8):41. PubMed ID: 27315067
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Defining the current role of immune checkpoint inhibitors in the treatment of mismatch repair-deficient/microsatellite stability-high colorectal cancer and shedding light on future approaches.
    Tan E; Sahin IH
    Expert Rev Gastroenterol Hepatol; 2021 Jul; 15(7):735-742. PubMed ID: 33539189
    [No Abstract]   [Full Text] [Related]  

  • 27. Mutational analysis of microsatellite-stable gastrointestinal cancer with high tumour mutational burden: a retrospective cohort study.
    Wang J; Xiu J; Farrell A; Baca Y; Arai H; Battaglin F; Kawanishi N; Soni S; Zhang W; Millstein J; Shields AF; Grothey A; Weinberg BA; Marshall JL; Lou E; Khushman M; Sohal DPS; Hall MJ; Liu T; Oberley M; Spetzler D; Korn WM; Shen L; Lenz HJ
    Lancet Oncol; 2023 Feb; 24(2):151-161. PubMed ID: 36681091
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Transcriptome and Network Dissection of Microsatellite Stable and Highly Instable Colorectal Cancer.
    Akbari V; Kallhor M; Mollashahi B; Movafagh A
    Asian Pac J Cancer Prev; 2019 Aug; 20(8):2445-2454. PubMed ID: 31450919
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Potential Value of Immunotherapy in Colorectal Cancers: Review of the Evidence for Programmed Death-1 Inhibitor Therapy.
    Toh JWT; de Souza P; Lim SH; Singh P; Chua W; Ng W; Spring KJ
    Clin Colorectal Cancer; 2016 Dec; 15(4):285-291. PubMed ID: 27553906
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Extended microsatellite analysis in microsatellite stable, MSH2 and MLH1 mutation-negative HNPCC patients: genetic reclassification and correlation with clinical features.
    Schiemann U; Müller-Koch Y; Gross M; Daum J; Lohse P; Baretton G; Muders M; Mussack T; Kopp R; Holinski-Feder E
    Digestion; 2004; 69(3):166-76. PubMed ID: 15118395
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neoadjuvant Immune Checkpoint Inhibitor Therapy for Patients With Microsatellite Instability-High Colorectal Cancer: Shedding Light on the Future.
    Sahin IH; Zhang J; Saridogan T; Gorantla V; Rhree J; Malhotra M; Thomas R; Hsu D; Saeed A
    JCO Oncol Pract; 2023 May; 19(5):251-259. PubMed ID: 36862965
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Application of immune checkpoint inhibitors in colorectal cancer.
    Wang L; Huang C
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2021 Aug; 46(8):894-899. PubMed ID: 34565736
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tumor-Infiltrating Lymphocytes in Colorectal Cancer: The Fundamental Indication and Application on Immunotherapy.
    Bai Z; Zhou Y; Ye Z; Xiong J; Lan H; Wang F
    Front Immunol; 2021; 12():808964. PubMed ID: 35095898
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Genomic and transcriptomic analysis of MSI-H colorectal cancer patients with targetable alterations identifies clinical implications for immunotherapy.
    Hua H; He W; Chen N; He Y; Wu G; Ye F; Zhou X; Li Y; Ding Y; Zhong W; Teng L; Jiang W; Sheng Q
    Front Immunol; 2022; 13():974793. PubMed ID: 36700211
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Relationship between microsatellite status and immune microenvironment of colorectal cancer and its application to diagnosis and treatment.
    Bai J; Chen H; Bai X
    J Clin Lab Anal; 2021 Jun; 35(6):e23810. PubMed ID: 33938589
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Regorafenib in combination with immune checkpoint inhibitors for mismatch repair proficient (pMMR)/microsatellite stable (MSS) colorectal cancer.
    Akin Telli T; Bregni G; Vanhooren M; Saude Conde R; Hendlisz A; Sclafani F
    Cancer Treat Rev; 2022 Nov; 110():102460. PubMed ID: 36058142
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A subset of patients with MSS/MSI-low-colorectal cancer showed increased CD8(+) TILs together with up-regulated IFN-γ.
    Kikuchi T; Mimura K; Okayama H; Nakayama Y; Saito K; Yamada L; Endo E; Sakamoto W; Fujita S; Endo H; Saito M; Momma T; Saze Z; Ohki S; Kono K
    Oncol Lett; 2019 Dec; 18(6):5977-5985. PubMed ID: 31788072
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Deficient mismatch repair/microsatellite unstable colorectal cancer: Diagnosis, prognosis and treatment.
    Taieb J; Svrcek M; Cohen R; Basile D; Tougeron D; Phelip JM
    Eur J Cancer; 2022 Nov; 175():136-157. PubMed ID: 36115290
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Role of the cGAS-STING pathway in regulating the tumor-immune microenvironment in dMMR/MSI colorectal cancer.
    Kaneta A; Nakajima S; Okayama H; Matsumoto T; Saito K; Kikuchi T; Endo E; Ito M; Mimura K; Kanke Y; Saito M; Saze Z; Fujita S; Sakamoto W; Onozawa H; Momma T; Ohki S; Kono K
    Cancer Immunol Immunother; 2022 Nov; 71(11):2765-2776. PubMed ID: 35429245
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Differential expression of CD133 based on microsatellite instability status in human colorectal cancer.
    Park JJ; Kwon JH; Oh SH; Choi J; Moon CM; Ahn JB; Hong SP; Cheon JH; Kim TI; Kim H; Kim WH
    Mol Carcinog; 2014 Feb; 53 Suppl 1():E1-10. PubMed ID: 23065858
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 76.